JTO Clinical and Research Reports

Additional Metrics

Top Publications

• Catalog of 5' Fusion Partners in ALK-positive NSCLC Circa 2020.

  Sai-Hong Ignatius Ou;Viola W. Zhu;Misako Nagasaka

  (2020)
  114 Citations

• Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC

  (2022)
  108 Citations

• Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC

  (2020)
  75 Citations

• Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1-Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042.

  Aaron S. Mansfield;Roy S. Herbst;Gilberto de Castro;Rina Hui

  (2021)
  56 Citations

• The Role of Interleukin 1β in the Pathogenesis of Lung Cancer.

  Edward B. Garon;James Chih-Hsin Yang;Steven M. Dubinett

  (2020)
  48 Citations

• Sex Differences in Lung Cancer Treatment and Outcomes at a Large Hybrid Academic-Community Practice

  (2022)
  46 Citations

• A Catalog of 5’ Fusion Partners in ROS1-Positive NSCLC Circa 2020

  (2020)
  44 Citations

• Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC

  (2022)
  44 Citations

• Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC

  (2022)
  43 Citations

• Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in BAP1 Gene.

  Azam Ghafoor;Idrees Mian;Cathy Wagner;Yvonne Mallory

  (2021)
  41 Citations